Media Releases  – 

BioHorizons Camlog launches Striate+™ – a collagen membrane at the cutting-edge of performance

The combination of superior handling, optimal durability, apparent osteoconductivity, and enhanced clinical outcomes makes Striate+ a membrane of choice for guided bone and tissue regeneration.

BioHorizons Camlog announced the launch of Striate+, an innovative collagen membrane developed by Orthocell Ltd. for advanced bone and tissue regeneration. BioHorizons Camlog and Orthocell Ltd have entered into a global distribution and manufacturing agreement for Striate+. The product strengthens BioHorizons Camlog’s position as a global provider of regenerative solutions for implant dentistry and covers the needs of a large portion of clinicians currently looking to improve the outcomes of their surgical procedures. Striate+ is exclusively available from BioHorizons Camlog.

Striate+ is manufactured from porcine-derived raw materials, selectively sourced from Australian veterinary-certified animals. The manufacturing process referred to as Scaffold Matrix Regenerative Therapy (SMRT™), removes immunogenic contaminants and ensures high biocompatibility while preserving the structure of the native collagen. The absence of any chemical modification or crosslinking promotes the integration of Striate+ with the surrounding soft tissues and can help minimise the risk of wound dehiscence. Striate+ is fully resorbed through physiological processes within 26 weeks, so a second surgical intervention to remove Striate+ is not necessary.

Furthermore, Striate+ exhibited excellent handling and usability. It can be applied without prior hydration and will gently conform and adhere to the defect contours without fixation yet can be stabilised by suturing and pinning if needed. A recent comparative study demonstrated that Striate+ had a higher mechanical strength than a leading competitor product1. The membrane absorbs fluids by capillarity but doesn’t excessively swell, which facilitates the primary closure and makes it particularly suitable for patients with thin phenotypes.

Striate+ has a bilayer structure with a rough and a smooth side. The smooth side, comprising of densely packed collagen fibers, acts as a barrier to the infiltration of gingival cells while allowing the passage of bioactive molecules1. Conversely, the rough side, composed of loosely distributed collagen fibers, provides a scaffold for osteoprogenitor cells to deposit osteoid. This results in an active promotion of bone formation and allows for early implant placement.

Striate+ is now exclusively available for ordering through BioHorizons Camlog in Belgium, France, Ireland, Italy, Netherlands, Portugal, Spain and UK. For further information about Striate+ please visit


1 Allan et al. Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications. Tissue Eng Part A. 2021. 27:372-381. 


Download press release

Download image




Dr. Redouan Mahou 
Brand Manager Biomaterials EMEA
Telephone: +41 79 481 31 23

Christina Ritchie
Head of Marketing Communication BioHorizons Camlog
Telephone: +41 79 593 07 74

Stefanie Fleige
Director, Corporate Media Relations – EMEA, Henry Schein
Telephone: +49 172 6433 548


About BioHorizons Camlog

BioHorizons Camlog is a leading supplier of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. It is committed to developing evidence-based and scientifically proven products, as well as continuing education adhering to highest standards.

Headquartered in the U.S (BioHorizons Inc. and associates) and Europe (Camlog Biotechnologies GmbH and associates), BioHorizons Camlog’s geographic positions allow it to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as its entire distribution network in more than 90 countries around the world.

Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.

For more information, visit and